Acrivon Therapeutics, the Watertown, Massachusetts-based clinical stage biopharmaceutical company, has appointed Adam Levy as its new head of IR and corporate affairs.
Most recently, Levy worked as senior vice president of IR at Zentalis Pharmaceuticals. Prior to that, he served as senior vice president of IR and corporate communications at Turning Point Therapeutics, which, during his time there, was acquired by Bristol Myers Squibb for $4.1 bn.
Levy has also held senior IR, corporate development and strategy roles at a range of healthcare companies, including Alaunos Therapeutics, Gilead Sciences, Alexion Pharmaceuticals and Novartis.
Earlier in his career, Levy served as an engagement manager at McKinsey & Co within the firm’s pharma practice. He holds an MBA from the Kellogg School of Management at Northwestern University and a PHD in molecular biology from the University of Illinois Chicago.
Sharpening communications and corporate affairs
‘We are thrilled to have Adam join us as a proven leader in investor relations and corporate strategy,’ comments Peter Blume-Jensen, CEO, president and founder of Acrivon, in a statement.
‘Adam has demonstrated a keen ability to effectively communicate novel scientific concepts and narratives in a highly cogent, constructive manner… Adding Adam to the team reflects our commitment to further sharpening our communications and corporate affairs.’
In a comment to IR Magazine, Levy says: ‘As a science-driven biotech, Acrivon is advancing rapidly at the cutting edge of proteomics. The AP3 technology platform, the experienced team and a winning culture make it a very compelling opportunity for me as an IR professional.’
